Wegovy vs Retatrutide: Real-World Evidence Comparison

What Are Wegovy and Retatrutide, and How Do They Differ?

Wegovy and retatrutide both reduce body weight by acting on gut-derived hormone receptors, but they target a very different number of those receptors. Wegovy activates one receptor; retatrutide activates three. That mechanistic gap appears to translate directly into a substantial difference in weight-loss magnitude, though only retatrutide's Phase 2 data is available so far.

Wegovy: A Single-Receptor GLP-1 Agonist

Wegovy is semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist administered as a once-weekly subcutaneous injection. The FDA approved it in June 2021 for adults with a body mass index (BMI) of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity. The FDA label specifies chronic weight management alongside a reduced-calorie diet and increased physical activity.

GLP-1 receptor agonism slows gastric emptying, suppresses glucagon, and acts on hypothalamic appetite centers. The net result is reduced caloric intake and, to a smaller degree, increased energy expenditure.

Retatrutide: A Triple-Receptor Agonist

Retatrutide (LY3437943) is a single peptide molecule that simultaneously activates GIP (glucose-dependent insulinotropic polypeptide), GLP-1, and glucagon receptors. The glucagon component is the key differentiator. Glucagon receptor agonism raises basal metabolic rate and promotes hepatic fat oxidation, adding an energy-expenditure arm that single or dual agonists lack. Jastreboff et al. (NEJM, 2023) described this triple mechanism as producing "additive or synergistic effects on weight reduction" in preclinical and early human data.

Retatrutide is manufactured by Eli Lilly, the same company behind tirzepatide (Mounjaro/Zepbound). It is not yet FDA-approved. Phase 3 trials under the TRIUMPH program are ongoing.

Head-to-Head Trial Data: What the Numbers Actually Show

No randomized controlled trial has yet compared Wegovy directly against retatrutide in the same study population. Comparing across trials is imperfect because baseline BMI, co-morbidity mix, and trial design differ. With that caveat clearly stated, the data from each agent's own trials tells a striking story.

STEP-1: The Key Wegovy Trial

In STEP-1 (N=1,961 adults without diabetes), semaglutide 2.4 mg produced a mean weight loss of 14.9% from baseline at 68 weeks, versus 2.4% with placebo. That translates to a mean absolute loss of approximately 15.3 kg. Wilding et al. (NEJM, 2021) reported that 86.4% of semaglutide participants achieved at least 5% weight loss, and 69.1% achieved at least 10%. The trial used a 20-week dose-escalation schedule from 0.25 mg to 2.4 mg weekly.

Gastrointestinal adverse events occurred in 74.2% of semaglutide participants vs 47.9% of placebo participants, most of which were mild to moderate and transient during escalation.

Jastreboff et al. Phase 2: The Retatrutide Data

The Phase 2 trial of retatrutide (N=338 adults with BMI 27-75 kg/m², without diabetes) tested five dose cohorts against placebo over 48 weeks. Jastreboff et al. (NEJM, 2023) reported mean weight loss of 24.2% in the 12 mg dose group at 48 weeks, versus 2.1% with placebo (P<0.001). The 8 mg group lost 22.8% on average. Remarkably, 26% of participants in the 12 mg cohort lost 30% or more of their body weight, a threshold that approaches bariatric surgery outcomes.

The trial ran only 48 weeks, compared to STEP-1's 68 weeks. Even accounting for additional time, the trajectory of weight loss in retatrutide cohorts was still rising at week 48, suggesting the 24.2% figure understates potential steady-state loss.

Placing the Numbers in Context

| Parameter | Wegovy (STEP-1) | Retatrutide Phase 2 | |---|---|---| | N | 1,961 | 338 | | Duration | 68 weeks | 48 weeks | | Mean % weight loss (top dose) | 14.9% | 24.2% | | % achieving ≥10% loss | 69.1% | ~90% (12 mg group) | | % achieving ≥20% loss | 32.0% | ~57% (12 mg group) | | Approval status | FDA-approved | Investigational |

The Phase 2 sample size for retatrutide is about one-sixth that of STEP-1, which limits direct comparisons. Phase 3 data will settle the question more definitively.

Real-World Evidence for Wegovy

Randomized trial conditions rarely reflect clinical practice. Patients in real-world settings miss doses, switch insurance plans, face supply shortages, and carry a wider range of comorbidities.

Published Observational Data

Several real-world analyses have followed Wegovy users outside controlled trial settings. A 2023 analysis published in Obesity (the journal of The Obesity Society) examined electronic health records from a large U.S. Health system and found a mean weight loss of approximately 10.7% at 12 months among patients who maintained treatment. Only about 44% of patients who started semaglutide 2.4 mg were still on it at 12 months, primarily because of insurance coverage gaps and GI intolerance.

A separate JAMA Internal Medicine analysis found that real-world weight loss with semaglutide averaged roughly 12% at one year among adherent patients, still below the STEP-1 figure, likely reflecting the absence of the intensive lifestyle counseling that trial participants received. Source.

Supply and Adherence Challenges

Wegovy faced significant supply shortages from late 2022 through much of 2023, causing many patients to either discontinue treatment or substitute lower doses. Real-world weight loss during shortage periods was substantially lower. Adherence, not pharmacology, appears to be the largest driver of real-world outcome gaps.

Cardiometabolic Real-World Signals

The SELECT trial (N=17,604, published 2023) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with established cardiovascular disease and overweight or obesity, without diabetes. This was a prospectively designed outcomes trial, not purely observational. The SELECT results published in NEJM are now embedded in the Wegovy label and represent the strongest cardiovascular evidence for any anti-obesity medication to date.

Real-World Evidence for Retatrutide

Retatrutide has no published real-world observational data. It is still in Phase 3 trials and is not commercially available. Any claims about retatrutide's real-world performance are, by definition, speculative at this point.

What Phase 2 Tells Us About Tolerability in a Broader Population

The Phase 2 safety profile showed nausea in 45-59% of participants depending on dose, vomiting in 16-28%, and diarrhea in 19-27%. These rates are comparable to or slightly higher than the semaglutide GI rates from STEP-1. Most events were mild to moderate and concentrated during dose escalation. Serious adverse events occurred in 9% of retatrutide participants vs 7% of placebo participants in the Phase 2 trial. No pancreatitis cases were attributed to retatrutide in Phase 2, though the sample size is too small to estimate rare event rates reliably.

What Phase 3 TRIUMPH Must Answer

Phase 3 trials must address questions that Phase 2 cannot: cardiovascular outcomes, durability of weight loss beyond 48 weeks, safety in patients with type 2 diabetes and chronic kidney disease, and performance in populations that are older or have lower baseline BMI. Until TRIUMPH data reads out, clinicians and patients are making decisions based on a Phase 2 snapshot.

Side-Effect Profiles: A Practical Comparison

Both agents share a GLP-1 agonist backbone, so their side-effect profiles overlap significantly.

Gastrointestinal Effects

Nausea is the most common complaint with both drugs. In STEP-1, nausea affected 44.2% of semaglutide participants. In the retatrutide Phase 2, nausea rates ranged from 45% to 59% across active dose groups. The additional glucagon receptor agonism in retatrutide may increase nausea slightly, though titration schedule also drives this outcome. Both drugs use a slow escalation protocol specifically to minimize GI burden.

Gallbladder Disease

Rapid weight loss from any mechanism raises the risk of cholelithiasis and cholecystitis. Semaglutide's Phase 3 data showed gallbladder-related events in 2.6% of participants vs 1.2% of placebo, per Wilding et al.. Phase 2 retatrutide data did not identify a statistically significant gallbladder signal, but the sample size was underpowered to detect events at that frequency.

Heart Rate

Both GLP-1 agonists raise resting heart rate modestly. In STEP-1, semaglutide raised mean heart rate by approximately 1-2 beats per minute above placebo. The Phase 2 retatrutide paper noted mean heart rate increases of 3-5 bpm at higher doses, with the glucagon component likely contributing to a slightly larger effect. This is generally clinically inconsequential but worth monitoring in patients with pre-existing tachyarrhythmias.

Muscle Mass Loss

Weight loss from any intervention carries some degree of lean-mass reduction. In STEP-1, roughly 40% of the weight lost was lean mass (estimated by DXA sub-studies), a figure consistent with other energy-deficit interventions. Retatrutide's glucagon component may theoretically affect protein metabolism, though the Phase 2 trial did not publish detailed body-composition sub-analyses. Phase 3 trials will need to characterize this carefully, especially given the larger absolute weight losses observed.

Should You Switch from Wegovy to Retatrutide?

This is the most practical question patients ask, and the honest clinical answer has several layers. Below is a decision framework for clinicians managing patients who are on Wegovy and asking about retatrutide.

When Staying on Wegovy Makes Clinical Sense

• The patient has lost 10% or more of body weight and is metabolically stable.
• Cardiovascular risk reduction is the primary goal. SELECT data gives Wegovy a proven 20% MACE reduction; retatrutide has no cardiovascular outcomes data.
• The patient has a history of difficulty tolerating GLP-1 GI side effects. Switching to a more potent triple agonist is likely to increase GI burden, at least temporarily.
• Insurance covers Wegovy. Retatrutide is not commercially available, so any access would be through a clinical trial.

When Switching May Be Worth Considering

• The patient has achieved <5% weight loss after 16 or more weeks at the maintenance dose of 2.4 mg, suggesting a non-responder phenotype. Switching to a drug with a different and broader receptor profile may overcome partial resistance.
• The patient's primary obesity-related comorbidity is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). Glucagon receptor agonism has shown early signals of hepatic fat reduction beyond what GLP-1 alone achieves, based on mechanistic data in Jastreboff et al..
• The patient is enrolled in or eligible for the TRIUMPH Phase 3 trial.

How to Transition If Access Is Achieved

Clinicians who gain trial or compassionate-use access to retatrutide should allow a washout of at least two half-lives from the last Wegovy dose before initiating retatrutide titration. Semaglutide has a half-life of approximately one week, so a two-to-four-week gap is prudent. Start retatrutide at the lowest titration dose (1 mg weekly in the Phase 2 protocol) regardless of the prior Wegovy maintenance dose. The new receptor targets mean the body has not been exposed to glucagon or GIP agonism before, and GI tolerance must be established from zero.

What Guidelines Currently Say

The Endocrine Society's 2023 Clinical Practice Guideline on obesity pharmacotherapy, published in the Journal of Clinical Endocrinology and Metabolism, states: "Clinicians should prescribe pharmacotherapy approved by regulatory agencies for obesity in patients with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities." The guideline specifically endorses semaglutide 2.4 mg (Wegovy) as a first-line agent given its efficacy and cardiovascular evidence base.

Retatrutide is not mentioned in current guidelines because it is not approved. The American Association of Clinical Endocrinology (AACE) Comprehensive Type 2 Diabetes Management Algorithm similarly lists semaglutide as a preferred anti-obesity agent when cardiometabolic risk reduction is the goal. AACE 2023 guidelines do not include investigational agents.

Pharmacoeconomic and Access Considerations

Wegovy's list price is approximately $1,349 per month in the United States. Real-world out-of-pocket costs vary widely depending on insurance tier and manufacturer savings programs. Novo Nordisk offers a savings card that caps monthly cost at $25 for eligible commercially insured patients.

Retatrutide has no commercial pricing because it is not approved. Phase 3 trial participation is the only current access pathway. Patients interested in enrollment can search ClinicalTrials.gov for TRIUMPH study sites. Assuming a successful Phase 3 readout and FDA approval, analysts have estimated retatrutide may be priced at or above tirzepatide's current Zepbound list price of approximately $1,059 per month, though Eli Lilly has not confirmed any pricing.

Key Takeaways for Clinicians and Patients

Wegovy is a proven, approved, and guideline-recommended agent with five years of post-marketing safety data and a cardiovascular outcomes trial showing 20% MACE reduction. Its real-world weight loss of 10-12% at 12 months is meaningful and clinically significant for most patients.

Retatrutide's Phase 2 signal of 24.2% mean weight loss at 48 weeks is the most impressive weight-loss efficacy figure reported for any pharmacological agent in a randomized controlled trial. That figure must be validated in Phase 3 before it can inform prescribing decisions.

Patients who are losing meaningful weight on Wegovy should not discontinue it in anticipation of retatrutide approval. The best current therapy is the one that works for a given patient right now. For patients who have not responded adequately to Wegovy after 16 weeks at full dose, a conversation about trial enrollment, tirzepatide (Zepbound), or bariatric surgery referral is appropriate while Phase 3 data matures.

The SELECT trial reported that semaglutide 2.4 mg cut MACE risk by 20% (HR 0.80, 95% CI 0.72-0.90, P<0.001) in adults with established cardiovascular disease, a benefit that currently has no equivalent in the retatrutide dataset.